Haskell-Luevano C, Boteju L W, Miwa H, Dickinson C, Gantz I, Yamada T, Hadley M E, Hruby V J
Department of Chemistry, University of Arizona, Tucson 85721, USA.
J Med Chem. 1995 Nov 10;38(23):4720-9. doi: 10.1021/jm00023a012.
We have introduced topographical constraints at the 9 position of a superpotent cyclic alpha-melanotropin analogue, Ac-Nle4-Asp5-His6-DPhe7-Arg8-Trp9-Lys10-NH2, by incorporating a methyl group at the beta-carbon of Trp9. These studies were performed on the Trp side chain pharmacophore to identify the bioactive topography of the indole moiety with melanocortin MC1 receptors. The four beta-MeTrp9 isomers, in addition to the stereochemical controls L- and DTrp9, were used to probe differential receptor molecular recognition of the tryptophan moiety in two bioassay systems. Approximately a 460-fold difference in potency was observed between the diastereoisomeric peptides in the frog skin bioassay, with only 33- and 10-fold efficacy differences observed in binding and intracellular cAMP accumulation, respectively, on the human melanocortin receptor, hMC1R. The relative orders of potencies in the frog skin bioassay were 2R,3S > 2S,3S = 2R,3R >> 2S,3R and for the hMC1R were 2S,3S > 2R,3R > 2R,3S >> 2S,3R. Of particular interest is the ability of these topographically constrained ligands to differentially affect prolonged biological activity. The 2R,3R diastereoisomeric peptide possessed superprolonged activity, whereas the 2S,3S peptide lacked any residual activity in the frog skin bioassay. However, on the melanocortin receptor, the 2S,3S diastereoisomeric peptide maintained slow dissociation rates (t1/2 = 7 h), while the other diastereoisomeric peptides possessed dissociation t1/2 rates of ca. 2 h. These data strongly implicate ligand-receptor interactions and kinetics as contributing to the observed prolonged biological activities and clearly illustrate topographical recognition differences between these two peripheral MC1 receptors involved in skin pigmentation. This study also demonstrates that topographical modifications of pharmacophore side chain residues, in addition to identifying preferential side chain orientation, can be a useful strategy for the design of peptides to increase the duration of biological activity, relative to the native ligand.
我们通过在Trp9的β-碳上引入一个甲基,在一种超强效环α-促黑素类似物Ac-Nle4-Asp5-His6-DPhe7-Arg8-Trp9-Lys10-NH2的9位引入了拓扑学限制。这些研究是在Trp侧链药效团上进行的,以确定吲哚部分与黑皮质素MC1受体的生物活性拓扑结构。除了立体化学对照L-和D-Trp9外,还使用了四种β-MeTrp9异构体,以在两种生物测定系统中探究色氨酸部分的差异受体分子识别。在蛙皮生物测定中,非对映异构肽之间观察到约460倍的效价差异,而在人黑皮质素受体hMC1R上,结合和细胞内cAMP积累中分别仅观察到33倍和10倍的效力差异。蛙皮生物测定中的效价相对顺序为2R,3S > 2S,3S = 2R,3R >> 2S,3R,而hMC1R的效价相对顺序为2S,3S > 2R,3R > 2R,3S >> 2S,3R。特别令人感兴趣的是这些拓扑学受限配体差异性影响延长生物活性的能力。2R,3R非对映异构肽具有超延长活性,而2S,3S肽在蛙皮生物测定中没有任何残留活性。然而,在黑皮质素受体上,2S,3S非对映异构肽保持缓慢的解离速率(t1/2 = 7小时),而其他非对映异构肽的解离t1/2速率约为2小时。这些数据强烈暗示配体-受体相互作用和动力学促成了观察到的延长生物活性,并清楚地说明了参与皮肤色素沉着的这两种外周MC1受体之间的拓扑识别差异。这项研究还表明,药效团侧链残基的拓扑修饰,除了确定优先侧链取向外,相对于天然配体而言,还可以是设计肽以增加生物活性持续时间的有用策略。